Macrophage dysfunction initiates colitis during weaning of infant mice lacking the interleukin-10 receptor

  1. Naresh S Redhu
  2. Vasudevan Bakthavatchalu
  3. Evan A Conaway
  4. Dror S Shoval
  5. Amy M Tsou
  6. Jeremy A Goettel
  7. Amlan Biswas
  8. Chuanwu Wang
  9. Michael Field
  10. Werner Muller
  11. Andre Bleich
  12. Ning Li
  13. Georg K Gerber
  14. Lynn Bry
  15. James G Fox
  16. Scott B Snapper  Is a corresponding author
  17. Bruce H Horwitz  Is a corresponding author
  1. Boston Children's Hospital, United States
  2. Massachusetts Institute of Technology, United States
  3. Brigham and Women's Hospital, United States
  4. University of Manchester, United Kingdom
  5. Hannover Medical School, Germany
  6. Harvard Medical School, United States

Abstract

Infants with defects in the interleukin 10 receptor (IL10R) develop very early onset inflammatory bowel disease. Whether IL10R regulates lamina propria macrophage function during infant development in mice and whether macrophage-intrinsic IL10R signaling is required to prevent colitis in infancy is unknown. Here we show that although signs of colitis are absent in IL10R-deficient mice during the first 2 weeks of life, intestinal inflammation and macrophage dysfunction begin during the 3rd week of life, concomitant with weaning and accompanying diversification of the intestinal microbiota. However, IL10R did not directly regulate the microbial ecology during infant development. Interestingly, macrophage depletion with clodronate inhibited the development of colitis, while the absence of IL10R specifically on macrophages sensitized infant mice to the development of colitis. These results indicate that IL10R-mediated regulation of macrophage function during the early postnatal period is indispensable for preventing the development of murine colitis.

Article and author information

Author details

  1. Naresh S Redhu

    Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Vasudevan Bakthavatchalu

    Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Evan A Conaway

    Department of Pathology, Brigham and Women's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Dror S Shoval

    Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Amy M Tsou

    Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Jeremy A Goettel

    Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Amlan Biswas

    Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4299-1001
  8. Chuanwu Wang

    Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Michael Field

    Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Werner Muller

    Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  11. Andre Bleich

    Institute for Laboratory Animal Science and Central Animal Facility, Hannover Medical School, Hannover, Germany
    Competing interests
    The authors declare that no competing interests exist.
  12. Ning Li

    Massachusetts Host-Microbiome Center, Department of Pathology, Brigham and Women's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Georg K Gerber

    Massachusetts Host-Microbiome Center, Department of Pathology, Brigham and Women's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9149-5509
  14. Lynn Bry

    Massachusetts Host-Microbiome Center, Department of Pathology, Brigham and Women's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. James G Fox

    Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Scott B Snapper

    Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, United States
    For correspondence
    Scott.Snapper@childrens.harvard.edu
    Competing interests
    The authors declare that no competing interests exist.
  17. Bruce H Horwitz

    Harvard Medical School, Boston, United States
    For correspondence
    bhorwitz@partners.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8123-8728

Funding

Crohn's and Colitis Foundation of America (RFA381023)

  • Naresh S Redhu

Canadian Institutes of Health Research (201411MFE-339308-254788)

  • Naresh S Redhu

National Institutes of Health (T32-OD010978-26)

  • James G Fox

Leona M. and Harry B. Helmsley Charitable Trust

  • Scott B Snapper

Wolpow Family Chair in IBD Research and Treatment

  • Scott B Snapper

National Institutes of Health (R01-OD011141)

  • James G Fox

National Institutes of Health (P30-ES002109)

  • James G Fox

National Institutes of Health (R01-AI00114)

  • Bruce H Horwitz

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Andrew J MacPherson, University of Bern, Switzerland

Ethics

Animal experimentation: All experiments were conducted following approval from the Animal Resources at Children's Hospital, per regulations of the Institutional Animal Care and Use Committees (IACUC assurance number A3303-01).

Version history

  1. Received: April 11, 2017
  2. Accepted: July 1, 2017
  3. Accepted Manuscript published: July 5, 2017 (version 1)
  4. Accepted Manuscript updated: July 7, 2017 (version 2)
  5. Version of Record published: July 27, 2017 (version 3)

Copyright

© 2017, Redhu et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,955
    views
  • 511
    downloads
  • 28
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Naresh S Redhu
  2. Vasudevan Bakthavatchalu
  3. Evan A Conaway
  4. Dror S Shoval
  5. Amy M Tsou
  6. Jeremy A Goettel
  7. Amlan Biswas
  8. Chuanwu Wang
  9. Michael Field
  10. Werner Muller
  11. Andre Bleich
  12. Ning Li
  13. Georg K Gerber
  14. Lynn Bry
  15. James G Fox
  16. Scott B Snapper
  17. Bruce H Horwitz
(2017)
Macrophage dysfunction initiates colitis during weaning of infant mice lacking the interleukin-10 receptor
eLife 6:e27652.
https://doi.org/10.7554/eLife.27652

Share this article

https://doi.org/10.7554/eLife.27652

Further reading

    1. Immunology and Inflammation
    Thomas Morgan Li, Victoria Zyulina ... Theresa T Lu
    Research Article Updated

    The autoimmune disease lupus erythematosus (lupus) is characterized by photosensitivity, where even ambient ultraviolet radiation (UVR) exposure can lead to development of inflammatory skin lesions. We have previously shown that Langerhans cells (LCs) limit keratinocyte apoptosis and photosensitivity via a disintegrin and metalloprotease 17 (ADAM17)-mediated release of epidermal growth factor receptor (EGFR) ligands and that LC ADAM17 sheddase activity is reduced in lupus. Here, we sought to understand how the lupus skin environment contributes to LC ADAM17 dysfunction and, in the process, differentiate between effects on LC ADAM17 sheddase function, LC ADAM17 expression, and LC numbers. We show through transcriptomic analysis a shared IFN-rich environment in non-lesional skin across human lupus and three murine models: MRL/lpr, B6.Sle1yaa, and imiquimod (IMQ) mice. IFN-I inhibits LC ADAM17 sheddase activity in murine and human LCs, and IFNAR blockade in lupus model mice restores LC ADAM17 sheddase activity, all without consistent effects on LC ADAM17 protein expression or LC numbers. Anti-IFNAR-mediated LC ADAM17 sheddase function restoration is associated with reduced photosensitive responses that are dependent on EGFR signaling and LC ADAM17. Reactive oxygen species (ROS) is a known mediator of ADAM17 activity; we show that UVR-induced LC ROS production is reduced in lupus model mice, restored by anti-IFNAR, and is cytoplasmic in origin. Our findings suggest that IFN-I promotes photosensitivity at least in part by inhibiting UVR-induced LC ADAM17 sheddase function and raise the possibility that anifrolumab ameliorates lupus skin disease in part by restoring this function. This work provides insight into IFN-I-mediated disease mechanisms, LC regulation, and a potential mechanism of action for anifrolumab in lupus.

    1. Immunology and Inflammation
    Xiaochan Xu, Bjarke Frost Nielsen, Kim Sneppen
    Research Article

    SARS-CoV-2 induces delayed type-I/III interferon production, allowing it to escape the early innate immune response. The delay has been attributed to a deficiency in the ability of cells to sense viral replication upon infection, which in turn hampers activation of the antiviral state in bystander cells. Here, we introduce a cellular automaton model to investigate the spatiotemporal spreading of viral infection as a function of virus and host-dependent parameters. The model suggests that the considerable person-to-person heterogeneity in SARS-CoV-2 infections is a consequence of high sensitivity to slight variations in biological parameters near a critical threshold. It further suggests that within-host viral proliferation can be curtailed by the presence of remarkably few cells that are primed for IFN production. Thus, the observed heterogeneity in defense readiness of cells reflects a remarkably cost-efficient strategy for protection.